Skip to main content
Công ty Cổ phần Dược phẩm Imexpharm logo

Công ty Cổ phần Dược phẩm Imexpharm — Investor Relations & Filings

Ticker · IMP ISIN · VN000000IMP0 HSX Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2024-04-22 Management Reports
Country VN Viet Nam
Listing HSX IMP

About Công ty Cổ phần Dược phẩm Imexpharm

www.imexpharm.com

Imexpharm Corporation is a prominent pharmaceutical company with over 48 years of experience in the manufacturing, compounding, and distribution of high-quality pharmaceutical products. The company operates extensive production facilities, including three EU-GMP certified factory clusters and one WHO-GMP certified cluster, making it a leader in EU-GMP compliant manufacturing. Imexpharm is recognized as a top producer of antibiotics and offers a diverse product portfolio encompassing injectable and oral antibiotics, cardiovascular, ophthalmic, musculoskeletal, respiratory, and digestive system treatments, alongside vitamins, minerals, and health protection foods. With 28 product registrations for 11 products in Europe, Imexpharm is dedicated to delivering effective and safe healthcare solutions to the community.

Recent filings

Filing Released Lang Actions
IMP: Giải trình chênh lệch KQKD Q1/2024 so với cùng kỳ năm trước
Management Reports Classification · 90% confidence The document is an explanatory note (‘giải trình’) addressed to securities regulators explaining >10% variances in Q1/2024 vs Q1/2023 key financial line items, including revenue, costs, profits and reasons for the fluctuations. It contains actual financial data in tabular form but is not a full interim report; rather it is management’s discussion and analysis of quarterly performance. This matches the Management Reports (MDA) category.
2024-04-22 Vietnamese
IMP: Link công bố báo cáo thường niên năm 2023
Report Publication Announcement Classification · 90% confidence The document is a disclosure on the securities regulator’s and exchange’s portals announcing a link to Imexpharm’s 2023 Annual Report. It contains no financial data itself, only a statement that the annual report is published and available via URL. Under the “Menu vs Meal” rule, this is not the report itself but an announcement of its publication. Therefore, it fits the Report Publication Announcement category.
2024-04-16 Vietnamese
IMP: Tài liệu họp ĐHĐCĐ thường niên năm 2024
Report Publication Announcement Classification · 85% confidence The document is a notice filed on the State Securities Commission and Ho Chi Minh Stock Exchange portals announcing that the company’s 2024 Annual General Meeting materials have been published on its website and can be downloaded. It does not contain the AGM materials themselves (slides, proxy statements, etc.) but merely announces their availability. This fits the definition of a Report Publication Announcement (RPA) rather than the actual AGM materials (AGM-R) or any financial report.
2024-04-08 Vietnamese
IMP: Giải trình chênh lệch KQKD năm 2023 so với năm trước
Regulatory Filings Classification · 85% confidence The document is a letter from Imexpharm to the State Securities Commission and HOSE explaining a >10% variance in annual financial results between 2022 and 2023. It is not an annual or interim report itself, nor a proxy, dividend notice, or earnings release. It is a required regulatory explanatory filing under Vietnamese securities rules, fitting the fallback category for miscellaneous regulatory announcements.
2024-03-29 Vietnamese
IMP: Thông báo thời gian, địa điểm và link cung cấp chương trình họp ĐHĐCĐ thường niên 2024
Regulatory Filings Classification · 68% confidence The document is a short periodic disclosure to the State Securities Commission and stock exchange announcing the date, time, venue, and agenda link for the 2024 Annual General Meeting. It does not contain the AGM materials themselves (slides or minutes), nor any voting results; rather it is a regulatory announcement. Under our menu‐vs‐meal rule it is an announcement (and under 5,000 characters), so it is not the report itself (e.g., AGM materials) but a generic regulatory filing. It therefore best fits the “Regulatory Filings” (RNS) category.
2024-03-26 Vietnamese
IMP: Thông báo về ngày ĐKCC tổ chức ĐHĐCĐ thường niên 2024
Regulatory Filings Classification · 85% confidence The document is a notice issued by the Ho Chi Minh Stock Exchange announcing the record date (“ngày đăng ký cuối cùng”) for shareholder eligibility in relation to the upcoming Annual General Meeting. It does not contain meeting materials, financial statements, proxy forms, voting results, or any substantive report data. It is a regulatory announcement for compliance with exchange requirements. Therefore, it falls under the general Regulatory Filings category (RNS).
2024-02-27 Vietnamese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.